Rajen I have done all that, plus quite a bit more. An inquiring mind would also establish with the recent collaboration that distal effects are in fact, not TT effects. You even answered that in your post...
With regard who benefits more, 99% Qbiotics. Have a look how many current studies are being done with Keytruda, and think who needs who more. If Qbiotics get positive results its a huge deal, with MSD able to open its vast abilities to pave the way to an approval. If not, we continue to stumble through early phase trials, with poor access to patients, burning cash, plus all the other roadblocks to small bio's in early stage trials.
Make of it what you will, you are entitled to your opinion.
